CompletedPhase 2

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

Brazil50 participantsStarted 2020-12-17

Plain-language summary

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Breast cancer hitologically confirmed * 18 Years and older (Adult, Older Adult) * Patients about to start use of Doxorubicine 60mg/m2 + Cyclophosfamide 600mg/m2 * No previous chemotherapy for breast cancer Exclusion Criteria: * Patients not capable of completing the questionnaire * Patients with other condition that could cause nausea and emesis * Use of opioids * Use of antipsychotic medications * Patients not capable of taking medications orally

What they're measuring

Nausea Complete Response Rate

Timeframe: 5 days after chemotherapeutic administration

Trial details

NCT IDNCT04669132

SponsorInstituto Brasileiro de Controle do Cancer

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-17

View on ClinicalTrials.gov More Nausea Post Chemotherapy trials